AZ to resume marketing Forxiga in Germany

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it will resume marketing Forxiga dapagliflozin in Germany after reaching an agreement with the country's Statutory Health Insurance Funds Association (GKV-Spitzenverband) on the price for the Type II diabetes drug. The pharma declined to disclose the negotiated price. In December, AZ and former partner Bristol-Myers Squibb Co. (NYSE:BMY) said they would stop marketing Forxiga in Germany after failing to reach an agreement on the product's price with GKV-Spitzenverband (see BioCentury Extra, Dec. 13, 2013). ...